Karyopharm Therapeutics selects CRO Clinipace as preferred provider

- Last updated on GMT

Karyopharm Therapeutics selects CRO Clinipace as preferred provider
Karyopharm Therapeutics has selected CRO Clinipace to help discover first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases, 

The selection comes as Karyopharm is looking to work with Clinipace in 2014 to manage several clinical programs, including ones in oncology, wound healing, and other diseases.

Karyopharm currently has two drugs in development to fight human cancer, including:

  • KPT-330 (Selinexor) is an XPO1 inhibitor being evaluated in multiple open-label Phase I clinical trials in patients with heavily pretreated relapsed and/or refractory hematological and solid tumor malignancies; and
  • KPT-350, which is being developed for the treatment of inflammatory disease.

Both companies declined to comment on the details of the deal and what trials would be run.

Sharon Shacham, Karyopharm’s founder, President and Chief Scientific Officer, said, “By partnering with a like-minded technology-driven company like Clinipace, we believe we can help accelerate our first-in-class small molecule modulators into effective targeted therapeutics for life threatening conditions​.”

As tailored therapies such as those Karyopharm have under development become more prominent, drug developers must find increasingly innovative ways to help bring their products to market in the most effective and efficient manner​,” said Jeff Williams, CEO and co-founder of Clinipace.  

Working with a technology-enabled digital CRO (dCRO) provides our clients with a significant level of information sharing that helps increase collaboration, improves data quality, and reduces their overall development costs​.”

Related news

Show more

Related products

VDS groß

Meet the challenges of complex injectables

Vetter Pharma International GmbH | 07-Nov-2017 | Technical / White Paper

In the time it takes from the exciting discovery phase to the rigorous demands of a commercial launch, unexpected scientific and technical challenges can...

lyo_vials

Process Development for Lyophilized Products

Baxter BioPharma Solutions | 30-Oct-2017 | Application Note

Baxter approaches formulation and process development with the intention of identifying the failure points for the product. Knowing where the product fails...

Ocopeptides

Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...

Related suppliers